Payment overview · 2025
General Payments
$692.93
29 reported records · 13 companies
Healthcare provider profile · identity verified
Alejandro Lerma, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SAN ANTONIO, TX · NPI 1679892566
Verified facts
What the public records show
CMS Open Payments records show Alejandro Lerma, M.D. received $692.93 in general payments during 2025 across 29 reported records.
Novo Nordisk Inc accounted for 23.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Gemtesa, Mounjaro, Ozempic, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 236 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $165.89 | 23.9% | 13 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $149.92 | 21.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $146.39 | 21.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $48.08 | 6.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.60 | 5.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.26 | 5.2% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.03 | 3.2% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $20.16 | 2.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.22 | 2.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.76 | 2.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.19 | 2.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.95 | 2.2% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $4.48 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $692.93 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $149.92 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $149.92 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $146.39 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $65.75 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $65.75 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $48.08 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $22.03 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $21.02 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $12.56 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $4.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 53 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 236 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 49 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
53 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
140 | 45 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
140 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
236 | 47 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
49 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
64 | 14 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
53 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 929 | 296 |
| Atorvastatin Calcium | Atorvastatin Calcium | 454 | 143 |
| Montelukast Sodium | Montelukast Sodium | 454 | 155 |
| Lisinopril | Lisinopril | 371 | 120 |
| Telmisartan | Telmisartan | 353 | 109 |
| Tramadol Hcl | Tramadol Hcl | 297 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 289 | 93 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 284 | 107 |
| Fluticasone Propionate | Fluticasone Propionate | 269 | 130 |
| Amlodipine Besylate | Amlodipine Besylate | 249 | 83 |
| Losartan Potassium | Losartan Potassium | 248 | 73 |
| Ozempic | Semaglutide | 236 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 224 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 190 | 60 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 189 | 27 |
| Pregabalin | Pregabalin | 181 | 75 |
| Tizanidine Hcl | Tizanidine Hcl | 179 | 76 |
| Gabapentin | Gabapentin | 173 | 70 |
| Metformin Hcl | Metformin Hcl | 155 | 52 |
| Omeprazole | Omeprazole | 155 | 51 |
| Jardiance | Empagliflozin | 140 | 45 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 135 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 120 | 38 |
| Finasteride | Finasteride | 111 | 40 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 94 | 26 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 93 | 23 |
| Nifedipine Er | Nifedipine | 92 | 30 |
| Furosemide | Furosemide | 91 | 36 |
| Metformin Hcl Er | Metformin Hcl | 91 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 30 |
| Fluconazole | Fluconazole | 84 | 57 |
| Carvedilol | Carvedilol | 80 | 26 |
| Mometasone Furoate | Mometasone Furoate | 80 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 80 | 26 |
| Sucralfate | Sucralfate | 78 | 20 |
| Trazodone Hcl | Trazodone Hcl | 78 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 27 |
| Bupropion Xl | Bupropion Hcl | 75 | 29 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 72 | 13 |
| Famotidine | Famotidine | 72 | 30 |
| Sertraline Hcl | Sertraline Hcl | 70 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 67 | 26 |
| Glipizide | Glipizide | 66 | 23 |
| Ibuprofen | Ibuprofen | 66 | 32 |
| Irbesartan | Irbesartan | 66 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 65 | 23 |
| Eliquis | Apixaban | 64 | 14 |
| Alprazolam | Alprazolam | 61 | 23 |
| Glimepiride | Glimepiride | 61 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 58 | 20 |
| Ipratropium Bromide | Ipratropium Bromide | 58 | 35 |
| Ketoconazole | Ketoconazole | 55 | 27 |
| Gemtesa | Vibegron | 53 | 23 |
| Linzess | Linaclotide | 53 | 18 |
| Enalapril Maleate | Enalapril Maleate | 51 | 15 |
| Zenpep | Lipase/Protease/Amylase | 51 | 24 |
| Allopurinol | Allopurinol | 49 | 16 |
| Rybelsus | Semaglutide | 49 | 20 |
| Amiloride Hcl | Amiloride Hcl | 46 | 19 |
| Meloxicam | Meloxicam | 46 | 29 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 46 | suppressed |
| Vascepa | Icosapent Ethyl | 46 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 44 | 15 |
| Januvia | Sitagliptin Phosphate | 43 | 13 |
| Megestrol Acetate | Megestrol Acetate | 42 | 23 |
| Desloratadine | Desloratadine | 41 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | 15 |
| Lidocaine | Lidocaine | 40 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 15 |
| Doxepin Hcl | Doxepin Hcl | 38 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 16 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 38 | suppressed |
| Glipizide Er | Glipizide | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Telmisartan-Amlodipine | Telmisartan/Amlodipine | 34 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 30 |
| Myrbetriq | Mirabegron | 33 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | 11 |
| Buspirone Hcl | Buspirone Hcl | 32 | 14 |
| Ezetimibe | Ezetimibe | 32 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 32 | suppressed |
| Lactulose | Lactulose | 31 | 18 |
| Lorazepam | Lorazepam | 31 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | 16 |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 29 | 11 |
| Vraylar | Cariprazine Hcl | 29 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 28 | 15 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 28 | suppressed |
| Colchicine | Colchicine | 27 | suppressed |
| Creon | Lipase/Protease/Amylase | 27 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | 12 |
| Tradjenta | Linagliptin | 27 | suppressed |
| Constulose | Lactulose | 26 | 15 |
| Lubiprostone | Lubiprostone | 26 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Jantoven | Warfarin Sodium | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | 11 |
| Enulose | Lactulose | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Estradiol | Estradiol | 16 | 11 |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 13 |
| Jentadueto | Linagliptin/Metformin Hcl | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 13 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Simvastatin | Simvastatin | 13 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Incontrol Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Permethrin | Permethrin | 11 | suppressed |
| Potassium Chloride | Potassium Chloride | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $692.93 · 29 records | Novo Nordisk Inc | ABRYSVO, Barostim Neo System, COMIRNATY, CREON, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, Heplisav-B, Kerendia, MOUNJARO, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, REPATHA, Rybelsus, VRAYLAR, Wegovy, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error